Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Type 1 diabetes can be detected years before symptoms appear — and new guidance wants to make that the standard. Spain's major diabetes societies have released a structured framework for presymptomatic T1D screening, targeting first-degree relatives and high-genetic-risk individuals. An international consensus backed by 20+ organizations is also pushing for general pediatric population screening, provided the right infrastructure is in place first.
Type 1 diabetes (T1D) doesn't just appear overnight — it silently progresses through autoimmune stages for years before symptoms emerge. Two new consensus documents are now pushing to change how we detect and manage the disease, advocating for structured presymptomatic screening programs that could dramatically reduce dangerous complications at diagnosis.
Spain's leading diabetes and endocrinology societies (SED, SEEN, SEEP) have jointly published an integrated care framework for identifying and monitoring individuals in the preclinical phases of T1D. Separately, an international consensus — convened by Breakthrough T1D and endorsed by 20+ global organizations — recommends general pediatric population screening, with suggested screening windows at ages 2–4, 6–8, and 10–15 years. Both frameworks rely on detecting islet autoantibodies (IAbs) in the blood as the key early warning signal.
By the Numbers:
Why it matters: Early detection reduces the risk of diabetic ketoacidosis (DKA) at diagnosis — a life-threatening emergency that also worsens long-term glycemic control. It also opens the door to therapeutic education, psychological support, and emerging therapies like teplizumab that can delay disease onset. While the ADA and AAP currently favor more targeted screening, momentum is clearly building toward broader, earlier detection.
